FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 上海市方达律师事务所 关于上海奥浦迈生物科技股份有限公司 2023 年限制性股票激励计划调整授予价格、作废部分限制性股票及 首次授予部分第二个归属期与预留授予部分第一个归属期归属 相关事项的法律意见书 权激励信息披露》适用的政府部门其他规章、规范性文件（以下合称"中国法律 法规"，仅为本法律意见书说明之目的，不包括中国香港特别行政区、中国澳门特 别行政区和中国台湾地区的法律、法规）的规定，出具本法律意见书。 为出具本法律意见书，本所律师审阅了《上海奥浦迈生物科技股份有限公司 章程》《上海奥浦迈生物科技股份有限公 ...

上海奥浦迈生物科技股份有限公司 关于续聘公司会计师事务所的公告 证券代码：688293 证券简称：奥浦迈 公告编号：2025-076 上海奥浦迈生物科技股份有限公司（以下简称"公司"或"奥浦迈"）于2025 年9月1日召开第二届董事会第十二次会议、第二届监事会第十一次会议，审议通 过了《关于续聘公司会计师事务所的议案》，同意续聘立信会计师事务所（特殊 普通合伙）为公司2025年度财务审计机构及内部控制审计机构。 一、拟聘任的会计师事务所的基本情况 （一）机构信息 1、基本信息 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由我国会计泰斗 潘序伦博士于1927年在上海创建，1986年复办，2010年成为全国首家完成改制的 特殊普通合伙制会计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。 立信是国际会计网络BDO的成员所，长期从事证券服务业务，新证券法实施前 具.有证券、期货业务许可证，具有H股审计资格，并已向美国公众公司会计监督 委员会（PCAOB）注册登记。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-077 上海奥浦迈生物科技股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、召开会议的基本情况 （一）股东大会类型和届次 2025年第二次临时股东大会 （二）股东大会召集人：董事会 （三）投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 （五）网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 股东大会召开日期：2025年9月19日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 网络投票起止时间：自2025 年 9 月 19 日 至2025 年 9 月 19 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-072 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届监事会第十一次会议于2025年9月1日通过通讯会议的方式召开。本次会议通知 及相关资料已于2025年8月22日送达全体监事。本次会议由监事会主席梁欠欠女 士召集并主持，会议应出席监事3名，实际出席监事3名，本次会议的召集、召开 方式符合相关法律、行政法规、部门规章、规范性文件和《公司章程》的规定， 会议决议合法有效。 二、监事会会议审议情况 经与会监事审议表决，形成的会议决议如下： 上海奥浦迈生物科技股份有限公司 第二届监事会第十一次会议决议公告 1、审议通过了《关于调整<公司2023年限制性股票激励计划>授予价格的议 案》 监事会认为：公司本次对2023年限制性股票激励计划授予价格（含预留）的 调整符合《上市公司股权激励管理办法》等法律法规以及《公司2023年限制性股 票激励计划（修订稿）》（以下简称"本激励计划 ...

上海奥浦迈生物科技股份有限公司 监事会关于公司 2023 年限制性股票激励计划首次授 予部分第二个归属期及预留授予部分第一个归属期 归属名单的核查意见 综上所述，监事会同意为本次符合归属条件的首次授予部分 43 名激励对象 及预留授予部分 45 名激励对象办理归属事宜，对应限制性股票的归属数量为 297,800 股。上述事项符合相关法律、法规及规范性文件所规定的条件，不存在 损害公司及股东利益的情形。 上海奥浦迈生物科技股份有限公司监事会 2025 年 9 月 1 日 上海奥浦迈生物科技股份有限公司（以下简称"公司"或"奥浦迈"）监事 会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称《" 证券法》"）、《上市公司股权激励管理办法》（以下简称《" 管 理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称《" 上市规则》"）、 《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等相关法律、法 规及规范性文件和《上海奥浦迈生物科技股份有限公司章程》（以下简称《" 公司 章程》"）的有关规定，对《公司 2023 年限制性股票激励计划（修订稿）》（以下 简 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-071 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届董事会第十二次会议于2025年9月1日通过通讯会议的方式召开。本次会议通知 及相关资料已于2025年8月22日送达全体董事。本次会议由董事长肖志华先生召 集并主持，会议应出席董事7名，实际出席董事7名，本次会议的召集、召开方式 符合相关法律、行政法规、部门规章、规范性文件和《公司章程》的规定，会议 决议合法有效。 二、董事会会议审议情况 经与会董事审议表决，形成的会议决议如下： 1、审议通过了《关于调整<公司2023年限制性股票激励计划>授予价格的议 案》 鉴于自公司2024年8月26日召开相关董事会审议《关于调整<公司2023年限制 性股票激励计划>授予价格的议案》至今，公司已完成2024年中期以及2024年年 度权益分派事项，根据《公司2023年限制性股票激励计划（修订稿）》（以下简 上海奥浦迈生物科技股份有限 ...

Group 1 - The core viewpoint of the news is that Aopumai's stock has shown significant volatility, with a year-to-date increase of 47.96% but a recent decline in the last five and twenty trading days [2] - As of August 29, Aopumai's stock price was 53.68 CNY per share, with a market capitalization of 6.095 billion CNY [1] - The company reported a revenue of 178 million CNY for the first half of 2025, representing a year-on-year growth of 23.77%, and a net profit of 37.55 million CNY, up 55.55% year-on-year [2] Group 2 - Aopumai's main business revenue composition includes 87.34% from products, 12.53% from services, and 0.13% from other sources [2] - The company is categorized under the pharmaceutical and biotechnology industry, specifically in the sub-sector of biological products [2] - As of June 30, 2025, Aopumai had 3,212 shareholders, an increase of 6.11% from the previous period, with an average of 24,100 circulating shares per shareholder, a decrease of 5.76% [2][3] Group 3 - Aopumai has distributed a total of 147 million CNY in dividends since its A-share listing [3] - Among the top ten circulating shareholders, ICBC Frontier Medical Stock A increased its holdings by 1.25 million shares, while other significant shareholders maintained their positions [3]

Core Viewpoint - The company reported significant revenue and profit growth in the first half of 2025, driven by strong performance in cell culture products and CDMO services [1][2]. Financial Performance - The company achieved revenue of 178 million yuan in the first half of 2025, representing a year-over-year increase of 23.77% [1]. - The net profit attributable to shareholders reached 38 million yuan, up 55.55% year-over-year, while the net profit after deducting non-recurring items was 30 million yuan, reflecting a 76.73% increase [1]. - In Q2 alone, revenue was 94 million yuan, showing a year-over-year growth of 47.21%, with net profit at 23 million yuan, a remarkable increase of 401.77% [1]. Business Segments - The product business, primarily focused on culture media, generated revenue of 155 million yuan in the first half of 2025, marking a year-over-year increase of 25.49% [2]. - The CDMO service business reported revenue of 22.27 million yuan, up 13.24% year-over-year [2]. - The strong performance in cell culture products, particularly through deep collaboration with overseas clients, significantly supported overall revenue growth [2]. Profitability and Cost Management - The gross margin for the product business improved to 71.91%, an increase of 1.57 percentage points year-over-year [2]. - The gross margin for CDMO services was -47.53%, a decrease of 43.01 percentage points year-over-year [2]. - The overall expense ratios for sales, management, and R&D were 7.40% (down 1.32 percentage points), 16.05% (down 14.06 percentage points), and 13.58% (up 2.87 percentage points) respectively [2]. Pipeline and Future Growth - As of mid-2025, the company had 282 confirmed drug development pipelines utilizing its culture media, an increase of 35 from the end of 2024 [2]. - The growth in pipelines spans various stages, with 11 projects commercialized, 32 in Phase 3, 32 in Phase 2, 58 in Phase 1, and 149 in preclinical stages, laying a solid foundation for future growth [3]. - The company adjusted its profit forecasts for 2025-2027 to net profits of 88 million, 128 million, and 174 million yuan respectively, reflecting a higher certainty in performance growth [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a robust revenue growth of 23.77% year-on-year in H1 2025, with total revenue reaching 178 million yuan. The net profit attributable to the parent company increased by 55.55% year-on-year to 38 million yuan [5] - The company is optimistic about the continued expansion of its overseas business and has raised its profit forecast for 2025-2027 [5] - The core product business is driving steady revenue growth, while the CDMO service business is showing signs of recovery [6] Financial Performance - In H1 2025, the company's product business generated revenue of 155 million yuan, a year-on-year increase of 25.49%, while the CDMO service business achieved revenue of 22 million yuan, up 13.24% [6] - The overseas revenue reached 69 million yuan, marking a significant year-on-year growth of 51.64%, accounting for 38.56% of total revenue [6] - The company’s gross margin improved to 56.84%, with the core cell culture product business gross margin at 71.91% [7] Profitability and Cost Management - The company’s net profit margin increased by 4.38 percentage points year-on-year to 20.96% in H1 2025, supported by effective cost control measures [7] - Management expenses decreased by 34.03% year-on-year, while R&D expenses rose by 56.97% to support new product development [7] Earnings Forecast - The company’s projected net profits for 2025-2027 are 75 million, 102 million, and 133 million yuan respectively, with corresponding EPS of 0.66, 0.90, and 1.18 yuan [5][9] - The current stock price corresponds to P/E ratios of 85.9, 62.9, and 48.0 for the years 2025, 2026, and 2027 respectively [5][9]

Investment Rating - The report maintains a "Recommended" rating for the company [1][10]. Core Views - The company has shown significant growth in both domestic and international performance, with an increase in the number of projects participated [1][9]. - The revenue for the first half of 2025 reached 178 million yuan, representing a year-over-year increase of 23.77%, while the net profit attributable to shareholders was 38 million yuan, up 55.55% year-over-year [5]. - The company’s product business, primarily focused on cell culture media, achieved a revenue of 155 million yuan, a year-over-year increase of 25.49% [9]. - The company has a growing pipeline with 282 confirmed drug development projects utilizing its media, an increase of 35 projects compared to the end of 2024 [9]. Financial Summary - The company’s total market capitalization is 6.3 billion yuan, with a circulating A-share market value of 4.3 billion yuan [1]. - The projected revenue for 2024 is 2.97 billion yuan, with a year-over-year growth of 22.3%, and net profit is expected to be 540 million yuan [7][12]. - The gross margin for the product business improved to 71.91%, while the CDMO service gross margin was -47.53% [9]. - The company’s asset-liability ratio is 8.2%, indicating a strong financial position [1].